Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.

Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R.

Drug Saf. 2020 Jan 31. doi: 10.1007/s40264-020-00904-9. [Epub ahead of print]

PMID:
32006348
2.

Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities.

Haroon M, Szentpetery A, Ashraf M, Gallagher P, FitzGerald O.

Clin Rheumatol. 2020 Jan 18. doi: 10.1007/s10067-020-04945-4. [Epub ahead of print]

PMID:
31955325
3.

Cardiovascular Comorbidities in Psoriatic Disease.

Szentpetery A, Haroon M, FitzGerald O.

Rheumatol Ther. 2020 Mar;7(1):5-17. doi: 10.1007/s40744-019-00185-4. Epub 2019 Dec 7. Review.

4.

Physiotherapist-Led Triage at a Rheumatology-Based Musculoskeletal Assessment Clinic: an 18-Month Service Evaluation of Activity and Outcomes.

Caffrey A, Smart KM, FitzGerald O.

ACR Open Rheumatol. 2019 May 17;1(4):213-218. doi: 10.1002/acr2.1022. eCollection 2019 Jun.

5.

Advanced musculoskeletal physiotherapy practice: The patient journey and experience.

Fennelly O, Blake C, FitzGerald O, Caffrey A, Fletcher L, Smart K, Corcoran S, Shé ÉN, Casserley-Feeney S, Desmeules F, Cunningham C.

Musculoskelet Sci Pract. 2020 Feb;45:102077. doi: 10.1016/j.msksp.2019.102077. Epub 2019 Nov 1.

PMID:
31731056
6.

Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
7.

Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.

Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhász B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szücs G, Szekanecz Z, Szamosi S, Szántó S.

Clin Rheumatol. 2020 Jan;39(1):167-175. doi: 10.1007/s10067-019-04771-3. Epub 2019 Sep 14.

PMID:
31522318
8.

Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
9.

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A.

Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19.

PMID:
31427438
10.

Opportunities and challenges in the treatment of psoriatic arthritis.

FitzGerald O, Ritchlin C.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):440-452. doi: 10.1016/j.berh.2019.03.001. Epub 2019 Apr 25. Review.

PMID:
31171314
11.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
12.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
13.

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O.

J Rheumatol Suppl. 2019 Jun;95:11-19. doi: 10.3899/jrheum.190118.

PMID:
31154399
14.

A multidisciplinary approach to reproductive healthcare in women with rheumatic disease.

Murray K, Moore L, O'Brien C, Clohessy A, Brophy C, FitzGerald O, Molloy ES, Mongey AB, Higgins S, Higgins MF, Minnock P, Lalor J, McAuliffe FM, Veale DJ.

Ir J Med Sci. 2020 Feb;189(1):237-243. doi: 10.1007/s11845-019-02040-5. Epub 2019 May 25.

PMID:
31129869
15.

Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis.

Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C, Miranda-Garcia M, Lavric M, Holzinger D, Pretzer C, Lainka E, Vastert SJ, de Roock S, FitzGerald O, Pennington SR, Foell D.

Ann Rheum Dis. 2019 Aug;78(8):1107-1113. doi: 10.1136/annrheumdis-2019-215051. Epub 2019 Apr 20.

PMID:
31005900
16.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Sep;46(9):1089-1096. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1.

17.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
18.

Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study

Murray C, Fearon C, Dockery M, Moran D, Heffernan E, Fitzgerald O, Veale DJ, Harty L.

Ir Med J. 2018 Oct 11;111(9):820.

PMID:
30556668
19.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
20.

Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease.

Haroon M, Gallagher P, FitzGerald O.

Ann Rheum Dis. 2019 Jul;78(7):1003-1004. doi: 10.1136/annrheumdis-2018-214583. Epub 2018 Dec 14. No abstract available.

PMID:
30552175
21.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

22.

Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meeting.

Abraham S, Barton A, Eder L, Lim A, McGonagle D, McHugh N, Pennington S, Sengupta R, Siebert S, Bowness P, Schafer PH, Cullen E, FitzGerald O.

Semin Arthritis Rheum. 2019 Jun;48(6):1005-1013. doi: 10.1016/j.semarthrit.2018.10.008. Epub 2018 Oct 15. No abstract available.

23.

Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.

Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L.

J Rheumatol. 2019 Mar;46(3):266-273. doi: 10.3899/jrheum.180195. Epub 2018 Nov 1.

PMID:
30385708
24.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.

Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.

25.

Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry.

Füssl F, Trappe A, Cook K, Scheffler K, Fitzgerald O, Bones J.

MAbs. 2019 Jan;11(1):116-128. doi: 10.1080/19420862.2018.1531664. Epub 2018 Nov 11.

26.

Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis.

Haroon M, Szentpetery A, Dodd JD, Fitzgerald O.

J Rheumatol. 2018 Aug;45(9):1329-1330. doi: 10.3899/jrheum.180299. No abstract available.

PMID:
30173181
27.

Vascular measures of atherosclerosis in detrusor overactivity and controls.

Ladanchuk T, Kwak S, Bates L, Parkin K, Harris K, Fitzgerald O, Lynch W, Moore KH.

Neurourol Urodyn. 2018 Nov;37(8):2827-2832. doi: 10.1002/nau.23784. Epub 2018 Aug 14.

PMID:
30106191
28.

Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?

De Marco G, McGonagle D, Mathieson HR, Merashli M, Magee C, FitzGerald O, Goodfield M, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Nov 1;57(11):2053-2055. doi: 10.1093/rheumatology/key199. No abstract available.

29.

Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey.

Fennelly O, Blake C, FitzGerald O, Breen R, O'Sullivan C, O'Mir M, Desmeules F, Cunningham C.

Musculoskeletal Care. 2018 Dec;16(4):425-432. doi: 10.1002/msc.1351. Epub 2018 Jun 21.

PMID:
29927063
30.

Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit.

Fennelly O, Blake C, FitzGerald O, Breen R, Ashton J, Brennan A, Caffrey A, Desmeules F, Cunningham C.

BMC Musculoskelet Disord. 2018 Jun 1;19(1):181. doi: 10.1186/s12891-018-2106-7.

31.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
32.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
33.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
34.

Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.

Murray KE, Moore L, O'Brien C, Clohessy A, Brophy C, Minnock P, FitzGerald O, Molloy ES, Mongey AB, Higgins S, Higgins MF, Mc Auliffe FM, Veale DJ.

Ir J Med Sci. 2019 Feb;188(1):169-172. doi: 10.1007/s11845-018-1829-7. Epub 2018 May 10. Review.

PMID:
29748892
35.
36.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

37.

Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain.

Cochrane A, Higgins NM, Rothwell C, Ashton J, Breen R, Corcoran O, FitzGerald O, Gallagher P, Desmond D.

J Occup Rehabil. 2018 Sep;28(3):559-567. doi: 10.1007/s10926-017-9748-4.

PMID:
29236203
38.

Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity.

Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O.

Arthritis Rheumatol. 2018 Mar;70(3):396-407. doi: 10.1002/art.40389. Epub 2018 Feb 6.

39.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

40.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331. doi: 10.1093/rheumatology/kex344.

41.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.

42.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

43.

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.

Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, Marzo-Ortega H, Helliwell PS, Feletar M, Ryan AW, Kane DJ, Korendowych E, Simpson MA, Packham J, McManus R, Brown MA, Smith CH, Barker JN, McHugh N, FitzGerald O, Warren RB, Barton A.

Ann Rheum Dis. 2017 Oct;76(10):1774-1779. doi: 10.1136/annrheumdis-2017-211414. Epub 2017 Aug 18.

44.

A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis.

Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M, James J, Lord J, Bowen C, de Wit M, Orbai AM, McHugh N; PROMPT study group.

J Rheumatol. 2017 Oct;44(10):1445-1452. doi: 10.3899/jrheum.161459. Epub 2017 Aug 1.

PMID:
28765241
45.

Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success.

Chambers GM, Paul RC, Harris K, Fitzgerald O, Boothroyd CV, Rombauts L, Chapman MG, Jorm L.

Med J Aust. 2017 Aug 7;207(3):114-118.

PMID:
28764619
46.

Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

McArdle A, Pennington S, FitzGerald O.

Clin Rev Allergy Immunol. 2018 Dec;55(3):271-294. doi: 10.1007/s12016-017-8630-7. Review.

PMID:
28748366
47.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

48.

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Szentpetery A, Heffernan E, Gogarty M, Mellerick L, McCormack J, Haroon M, Elmamoun M, Gallagher P, Kelly G, Fabre A, Kirby B, FitzGerald O.

Arthritis Res Ther. 2017 Jul 5;19(1):158. doi: 10.1186/s13075-017-1364-3.

49.

The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort.

O'Rourke M, Haroon M, Alfarasy S, Ramasamy P, FitzGerald O, Murphy CC.

J Rheumatol. 2017 Sep;44(9):1347-1354. doi: 10.3899/jrheum.170115. Epub 2017 Jul 1.

PMID:
28668811
50.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

Supplemental Content

Loading ...
Support Center